However, in both CLL and B-lymphoma cells, anti-IgM-induced PDCD4 down-regulation was due to increased proteasomal degradation as it was reversed by PSI, including bortezomib which is used to treat multiple myeloma and mantle cell lymphoma. This evidence concerns the gene CD40LG and AL amyloidosis.